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Abstract
Background: The apolipoprotein E (APOE) e4 allele has been reported to be a risk factor for Alzheimer’s disease (AD) and
dementia with Lewy bodies (DLB). Previous neuropathological studies have demonstrated similar frequencies of the APOE
e4 allele in AD and DLB. However, the few ante-mortem studies on APOE allele frequencies in DLB have shown lower
frequencies than post-mortem studies. One reason for this may be inaccuracy of diagnosis. We examined APOE genotypes
in subjects with AD, DLB, and a control group using the latest diagnostic criteria and MRI, SPECT, and MIBG myocardial
scintigraphy.
Methods: The subjects of this study consisted of 145 patients with probable AD, 50 subjects with probable DLB, and a
control group. AD subjects were divided into two groups based on age of onset: early onset AD (EOAD) and late onset AD
(LOAD). All subjects had characteristic features on MRI, SPECT, and/or myocardial scintigraphy.
Results: The rate of APOE4 carrier status was 18.3% and the frequency of the e4 allele was 9.7% in controls. The rate of
APOE4 carrier status and the frequency of the e4 allele were 47% and 27% for LOAD, 50% and 31% for EOAD, and 42% and
31% for DLB, respectively.
Conclusion: The APOE4 genotypes in this study are consistent with previous neuropathological studies suggesting accurate
diagnosis of AD and DLB. APOE4 genotypes were similar in AD and DLB, giving further evidence that the e4 allele is a risk
factor for both disorders.
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Introduction
The apolipoprotein E (APOE) e4 allele has been reported to
be a risk factor for Alzheimer’s disease (AD) [1,2]. APOE is a
major component of lipoproteins and plays a role in the
metabolism and redistribution of cholesterol [3]. APOE levels
increase after brain injury in some neurons and APOE can affect
neurite extension. Thus, it is thought to play an important role in
the repair and protection of neurons [4]. APOE exists as 3 major
alleles (e2, e3, and e4) that translate into three isoforms of the
protein (APO E2, E3, and E4). Persons being homozygous for
the e4 allele are more likely to develop the sporadic type of AD
[5].
APOE4 has also been implicated in the development of
dementia with Lewy bodies (DLB), thought to be the second most
common cause of dementia [6]. Previous neuropathological
studies have demonstrated that the frequency of the APOE e4
allele in DLB is similar to AD [7,8,9,10], suggesting a common
pathophysiology in the two disorders. However, the few
antemortem studies on APOE allele frequencies in DLB have
shown lower rates of APOE allele frequencies. One reason may be
low accuracy of DLB diagnosis. Previous antemortem studies have
not used the most current consensus diagnostic criteria for DLB
delineated by the DLB consortium in 2005 [11]. Additionally,
radiological testing such as MIBG myocardial scintigraphy was not
used for diagnosis.
In this study, we examined APOE genotypes in a population of
Japanese subjects diagnosed using relevant radiological testing
and the most current consensus diagnostic criteria for DLB and
AD.
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1. Subjects (Table 1)
The subjects of this study were 279 control subjects from one
of our previous studies [12], 145 patients with probable AD
according to the NINCDS/ADRDA criteria [13], and 50 subjects
with probable DLB according to the latest consensus diagnostic
criteria published in 2005 [11]. To obtain non-demented controls,
elderly individuals were recruited in Kitahiroshima, Japan and
were evaluated by a questionnaire that included an inquiry into
past and present illnesses. These population-based non-demented
controls consisted of 113 men and 166 women with a mean6
SD age at blood draw of 75.668.1 years. All AD subjects had
characteristic neuroimaging features such as atrophy of the
parahippocampal gyrus and the parietal lobe on MRI and
hypoperfusion in the regions beside the posterior cingulate gyrus
on 99mTc-ECD brain perfusion SPECT. They were divided into
two groups based on the age of onset; early onset AD (EOAD,
,65 y) and late onset AD (LOAD, 65 y and higher). Age of onset
was determined by interview of patient families. The EOAD group
included 16 patients whose mean age was 63.165.0 years and
male:female ratio was 7:9, while the LOAD group consisted of 129
patients whose mean age was 79.164.9 years and M:F ratio was
44:85. The DLB group consisted of 50 patients whose mean age
was 79.164.9 years and M:F ratio was 15:35. All DLB subjects
had preserved hippocampal volume on MRI demonstrated by an
automated volume measuring program named VARSD [14],
occipital hypoperfusion on brain perfusion SPECT revealed by
statistical analysis programs [15,16,17,18,19,20,21] and decreased
cardiac uptake of 123I- metaiodobenzylguanidine (MIBG) defined
as delayed heart-to-mediastinum (H/M) ratio lower than 1.83
[17,18,22].
The APOE genotyping was performed using the polymerase
chain reaction. Informed written consent was obtained from all
subjects and their relatives. This study was approved by the
institutional ethical committees at Sapporo Medical University.
2. Method
APOE genotyping (Figure 1). Using a QIAamp DNA Blood
Mini Kit (QIAGEN, Tokyo, Japan), genomic DNA was extracted
from the buffy coat after centrifugation of the blood sample (1 ml)
according to the manufacture’s instructions. DNA genotyping of
APOE was performed according to the protocol described by
Hixson and Vernier et al [23]. Briefly, leukocyte DNA was
amplified by PCR using the oligonucleotide primers Primer 1 (59-
TAAGCTTGGCACGGCTGTCCAAGGA-39) and Primer 2 (59-
ACAGAATTCGCCCCGGCCTGGTACAC-39) set on common
sequence parts of APOE isoforms. The PCR products were
digested with Hha1 (New England Biolabs. Japan Inc., Tokyo,
Japan) and the resulting digestion fragments were separated by
electrophoresis on polyacrylamide gels (SuperSepTMDNA 15%
gel(Wako, Tokyo, Japan)). Each genotype of APOE was
distinguished by unique combinations of Hha1 fragment sizes in
all homozygotic and heterozygotic combinations [23]. After
determining the APOE genotypes, we investigated the APOE4
carrier status and the frequency of the e4 allele in the 279 controls,
145 AD, and 50 DLB cases.
Statictical Analysis (Table 2). Differences in APOE carrier
status between groups were evaluated by the Cochran-Mantel-
Haenszel Test. It was used to test if there is a relationship between
patients (LOAD, EOAD, and DLB) and controls after blocking
across a third classification: Wild, Hetero (heterozygous), and
Homo (homozygous).That is to say, these comparisons was
performed in 263 contingency tables. The frequencies of the e4
allele between groups were compared in 262 contingency tables
using the Fisher’s Exact Test. All analyses were conducted with
JMP version 7 (SAS Institute Inc., Cary, NC).
Results
The results are shown in Table 2.
In the control group, 51 out of 279 subjects were APOE4
carriers (18.3%). Three subjects were homozygous for the e4 allele
(1.1%) and 48 subjects were heterozygous for the e4 allele
(17.2%).The total frequency of the e4 allele was 9.7%.
In the LOAD group, 61 out of 129 subjects were APOE4
carriers (47.3%). Nine subjects were homozygous for the e4 allele
(7.0%) and 52 subjects were heterozygous for the e4 allele (40.3%).
The total frequency of the e4 allele was 27.1%.
In the EOAD group, 8 out of 16 subjects were APOE4 carriers
(50%). Two subjects were homozygous for the e4 allele (12.5%)
and 6 subjects were heterozygous for the e4 allele (37.5%). The
total frequency of the e4 allele for this group was 31.3%.
In the DLB group, 21 out of 50 subjects were APOE4 carriers
(42%). Three subjects were homozygous for the e4 allele (6.0%)
and 18 subjects were heterozygous for the e4 allele (36%).The total
frequency of the e4 allele was 24%.
APOE carrier status was significantly different between LO
AD and controls (p,0.0001), between EOAD and controls
(p=0.0002), and between DLB and controls (p=0.0003). Allele
frequencies of APOE e4 were significantly higher in LOAD
(p,0.0001), EOAD (p=0.0011), and DLB (p,0.0002) than in
controls (Table 2). There were no significant differences in rates of
APOE4 carrier status (p=0.82) and the frequencies of the e4 allele
(p=0.59) between LOAD and DLB. No significant differences in
rates of APOE4 carrier status (p=0.66) and the frequencies of the
e4 allele (p=0.49) were found between EOAD and DLB.
Similarly, no significant differences were found in rates of APOE4
carrier status (p=0.73) and the frequencies of the e4 allele
(p=0.68) between LOAD and EOAD.
Discussion
This study examined the rate of APOE4 carrier status and the
frequency of the e4 allele in a group of non-demented subjects,
subjects with probable AD who were separated into early-onset
and late-onset groups, and subjects with DLB. A significant
difference in the distribution of APOE phenotypes was found
between each patient group (LOAD, EOAD, and DLB) and
controls. We found no significant difference in rates of APOE4
carrier status and the frequencies of the e4 allele between LOAD/
EOAD and DLB subjects. The APOE genotypes in our control
subjects are similar to those reported in control subjects from other
Japanese studies [24,25].
Table 1. Subject background.
Controls
late onset
AD
early onset
AD DLB
n 279 129 16 50
Sex (M:F) 113:166 44:85 7:9 15:35
Age (y) 75.668.1 79.164.9 63.165.0 79.164.9
Age at onset (y) 75.665.2 59.365.9 75.565.0
MMSE score 15.565.5 15.867.2 15.365.4
Period of education (y) 9.162.5 11.261.7 8.663.0
doi:10.1371/journal.pone.0018569.t001
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to previous postmortem studies examining APOE4 carrier status
and e4 allele frequencies. In postmortem studies examining
LOAD, the frequency of APOE4 carrier status ranges from 47%
to 59%, and that of the e4 allele ranges from 27% to 37% [7,8].
Regarding antemortem studies on LOAD, the frequency of
APOE4 carrier status is 40% to 59%, and that of the e4 allele is
24 to 31% [24,26,27]. Although there are only a few autopsy-
based studies that measure APOE4 in EOAD [7,10], the
frequency of APOE4 carrier and e4 allele was 52%–57% and
around 35%, respectively, in those studies. Previous antemortem
studies examining EOAD have been widely divergent. Okuizumi
et al. investigated 33 antemortem AD cases and 11 postmortem
cases and reported that the frequency of APOE4 carrier and e4
allele is 58% and 30%, respectively [28]. The frequency of
APOE4 carrier status and the e4 allele in EOAD was clinically
reported as 7% and 4% by Kawamata et al. [29], and 72% and
43% by Dai et al [30], respectively. The widely divergent results
suggest that antemortem studies, particularly involving EOAD,
might depend strongly on methodological differences. Our results
were consistent with previous postmortem studies in both LOAD
and EOAD, supporting the accuracy of our diagnoses.
Although there are many clinical [9,30] and autopsy-based
studies [31,32] measuring the e4 allele in AD, most do not
distinguish between EOAD and LOAD. However, both have
different genetic backgrounds [33], different rates of progression
[34], and different levels of impairment in verbal and visual
cognition [35,36]. Thus, it is necessary to distinguish EOAD from
LOAD for research purposes. The NINCDS/ADRDA criteria
support this notion and states that researchers should be aware of
two subtypes; ‘‘less than 65 y’’ and ‘‘65 y and higher’’ [13].
With regards to DLB, our results also closely matched
postmortem studies examining the frequencies of APOE4 carrier
status and the e4 allele. Several research groups from various
countries have conducted similar investigations with large samples
of postmortem brains of DLB patients [7,9,10]. The frequency of
APOE4 carrier status and the e4 allele in these studies ranged
from 36% to 65% and 19 to 36%, respectively. There have been
three previous antemortem studies that have reported the
frequency of APOE4 carrier status and the e4 allele in DLB
patients. Engelborghs et al. [32] reported the frequency of APOE4
carrier status and the e4 allele as 28.5% and 18%, respectively,
Carrillo et al. [31] indicated frequencies of 27.6% and 16.4%, and
Lane et al. [37] reported frequencies of 35% and 18.1%. These
frequencies are lower or at the lower end of the range of
frequencies determined by autopsy-based studies, as opposed to
our results which were more consistent with previous autopsy-
based studies.
Figure 1. ApoE isoform and Hha1cleavage maps. Each genotype of apoE was distinguished by unique combinations of Hha1 fragments.
Cys:Cysteine, Arg:Arginine.
doi:10.1371/journal.pone.0018569.g001
Table 2. ApoE4 carrier status and the frequency of the e4
allele in Controls, LOAD, EOAD, and DLB.
e2/2 e2/3 e3/3 e2/4 e3/4 e4/4
E4
carrier
e4
allele
Contols
N=279
0(0) 20(7.1) 208(74.6) 2(0.7) 46(16.5) 3(1.1) 18.3% 9.7%
LOAD N=129 0(0) 5(3.9) 63(48.8) 2(1.5) 50(38.8) 9(7.0) 47.3% 27.1%
EOAD N=16 0(0) 0(0) 8(50.0) 1(6.2) 5(31.3) 2(12.5) 50.0% 31.3%
DLB N=50 0(0) 5(10.0) 24(48.0) 2(4.0) 16(32.0) 3(6.0) 42.0% 24.0%
n( % ) .
doi:10.1371/journal.pone.0018569.t002
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patients with DLB may have an accelerated disease progression
and approximately 50% of patients experience life-threatening
adverse reactions to antipsychotic medications [38]. Our results
suggest that our clinical diagnosis of DLB and AD was quite
accurate. To accomplish the highest possible accuracy of
antemortem diagnosis of DLB, we performed MRI, brain
perfusion SPECT and MIBG myocardial scintigraphy in con-
junction with using the latest DLB diagnostic criteria. These
diagnostic guidelines [11] acknowledge the importance of the
types of neuroimaging findings found in our study such as relative
preservation of medial temporal lobe structures on MRI scan,
occipital hypoperfusion on brain perfusion SPECT and decreased
MIBG uptake on myocardial scintigraphy. We have previously
demonstrated the usefulness of these neuroimaging tools for the
clinical diagnosis of DLB [18,22]. Notably, all of the previous
antemortem studies [31,32,37] on APOE4 in DLB did not use or
were conducted before the publication of the current consensus
diagnostic criteria for DLB. Our study is the first antemortem
study to use the latest diagnostic criteria for DLB. The results of
our study suggest that the current criteria used in conjunction with
MIBG myocardial scintigraphy, MRI and PET is more accurate
in the diagnosis of DLB than previous diagnostic criteria.
There is a growing consensus that APOE allele frequency is
influenced by race [39]. This may explain why the frequency of
the e4 allele in autopsied DLB cases varies widely (19 to 36%). To
the best of our knowledge, there are no antemortem studies in
which APOE4 genotypes are characterized in Asian patients with
DLB. A prior meta-analysis found that the APOE e4 allele
association with AD was stronger in Japanese subjects than in
Caucasian subjects [39]. Our results suggest that the APOE e4
allele is more frequent in Japanese patients with DLB.
The role of APOE e4 in the pathophysiology of AD remains
controversial. However, it has been reported that the gene dose of
APOE e4 correlates with the expression of senile plaques (SP) and
neurofibrillary tangles (NFT) [2]. SPs are composed of amyloid-
beta protein (Ab) which is deposited outside the neuron. Previous
studies have revealed a large quantity of Ab deposition in the brain
of AD patients with APOE4 [40]. Ab deposition has been shown
in the neuropil and vessel walls of subjects with APOE4 [40].
Notably, the extent of Ab deposition in APOE4 homozygotes was
more severe than APOE4 heterozygotes [40]. On the other hand,
NFTs are composed of phosphorylated tau proteins that have
accumulated inside the neuron. Animal studies have revealed that
transgenic mice expressing human APOE4 had more phosphor-
ylated tau proteins [26].
Our results demonstrated similar frequencies of APOE4 carrier
status and the e4 allele in LOAD, EOAD and DLB. Indeed,
previous studies have revealed the commonality of pathological
findings in DLB and AD. Kosaka reported that many SPs and/or
NFTs are present in autopsy cases with DLB. According to his
report, DLB can be divided into two forms: a common form and a
pure form [41]. In the common form, numerous Lewy bodies can
be found with many SPs and/or NFTs in the cerebral cortex,
whereas in the pure form, there are few or no senile changes.
Kawanishi et al. also reported that SPs, a characteristic feature of
AD, were found in the autopsied brains of DLB patients [27]. We
speculate that DLB patients with AD pathology tend to have
higher frequencies of the e4 allele. Perhaps a higher portion of our
DLB patient sample have AD pathology, though due to the
antemortem nature of our study it is difficult to assess this.Given
the similar frequencies of e4 allele in AD and DLB in our study,
our results support the idea that there is often overlapping
pathology between AD and DLB and that APOE4 plays a role in
the pathophysiology of both disorders.
We must recognize some limitations in our study. The number
of subjects in our study was small, although we included 50
probable DLB cases, a number higher than previous studies. Also
we have not confirmed the diagnosis through neuropathological
means. Current guidelines suggest pathological confirmation to
give a definite diagnosis of DLB. However, our results suggest that
the combination of careful history taking, conscientious examina-
tion of clinical features, neuro-psychological cognitive tests, and
neuroimaging tools including MRI, brain perfusion SPECT and
MIBG myocardial scintigraphy could significantly increase the
preciseness of clinical diagnosis.
In conclusion, our study results give further support for APOE4
as a biological marker for the presence of DLB. Our results
demonstrated that the rate of APOE carrier status and the
frequency of the e4 allele in DLB were as high as in AD. Our
results were also consistent with postmortem studies suggesting
that our diagnosis including brain perfusion SPECT and MIBG
myocardial scintigraphy was accurate.
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